Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | withdrawn | Phase 2 | 0 | NGM Biopharmaceuticals, IncINDUSTRY | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07484282 | Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer(exBOND) | withdrawn | Phase 2 | 0 | CG Oncology, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas(CARMEN-803) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02450396 | Pregnancy and Medically Assisted Conception in Rare Diseases(EGR2) | withdrawn | — | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05188573 | EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients | withdrawn | N/A | 0 | ClearNote HealthINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05982522 | IN10018 Combination Therapy in Previously-treated Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 0 | Mar 27, 2026 | clinicaltrials |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | withdrawn | — | 0 | Methodist Health SystemOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT06713798 | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures(INDIGO) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 0 | Mar 18, 2026 | clinicaltrials |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06654050 | Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | withdrawn | N/A | 0 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer | withdrawn | Phase 1 | 0 | Rush University Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07137390 | A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 11, 2026 | clinicaltrials |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions(VAPEX) | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT06292975 | Exercise for Improving Radiotherapy Efficacy in Rectal Cancer | withdrawn | N/A | 0 | University of HullOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04243473 | Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population | withdrawn | N/A | 0 | Timser SAPI de CVINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | withdrawn | — | 0 | Cofactor Genomics, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439432 | Stereotactic Guided Biopsy and Cryoablation | withdrawn | N/A | 0 | Montefiore Medical CenterOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT05014295 | Patient Recall of Cancer Screening and Diagnosis | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Feb 24, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06603818 | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03027986 | Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy(PROTOMEN) | withdrawn | N/A | 0 | University Hospital, RouenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05487859 | Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05799612 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT06284460 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer(DISCORDANT) | withdrawn | Phase 3 | 0 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer.(FOODPANC) | withdrawn | N/A | 0 | Fundacion para la Excelencia y la Calidad de la OncologiaOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT06501989 | Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Inova Health Care ServicesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07323576 | A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer(INAVO-CRC) | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Feb 9, 2026 | clinicaltrials |
| NCT05488626 | Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer(ARTIA-Lung) | withdrawn | N/A | 0 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06098755 | The Sequestration of Holistic Stress Management Techniques for Adults | withdrawn | N/A | 0 | Goddess Zena I. JonesOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | withdrawn | N/A | 0 | University of OklahomaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation(Mandolin) | withdrawn | Phase 2 | 0 | Epizyme, Inc.INDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT05044312 | Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | withdrawn | Phase 2 | 0 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 0 | Jan 22, 2026 | clinicaltrials |
| NCT06922825 | Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients | withdrawn | Early Phase 1 | 0 | Eben RosenthalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03135743 | Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012(LYMPHOSYNCHRO) | withdrawn | — | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 0 | Jan 16, 2026 | clinicaltrials |
| NCT05329870 | Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test (qFIT) Results? | withdrawn | — | 0 | University of EdinburghOTHER | 1 | Jan 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials